Search Results

Boundless Bio today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761).

Boundless Bio presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.

IBEX Technologies Inc. announces that it has completed the sale of the company by amalgamating with 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited.

IBEX Technologies Inc. is pleased to announce that at an annual and special meeting held , IBEX shareholders approved the previously-announced proposed amalgamation of IBEX and 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited, whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash.

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI ® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors.

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO ® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors.

BBI-001 was well tolerated with no dose limiting toxicities. Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.

Boundless Bio today will present preclinical data on its second ecDNA-directed therapy (ecDTx), BBI-825, as well as present additional research on the intrinsic genomic plasticity of cancer cells enabled by ecDNA at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 (the “ Acquisition Agreement ”) and related agreements with 15720273 Canada Inc. (the “ Purchaser ”), a newly-incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited (“ BBI ”), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.

Bond Biosciences has a clear path for the submission of an IND application to the FDA in the fourth quarter of 2024.